Trade AstraZeneca ^AZN

GCC Growth Summit 2026: Can Indian GCCs Effectively Navigate the Challenge of Saying No?, ETGCC

AstraZeneca Confident Rare-Disease Drug Can Hit Target After Mixed Study Results - Update | Morningstar

Ovarian Cancer Drugs Market Outlook Report 2026-2030 Featuring Strategic Analysis of AstraZeneca, Roche, Bristol-Myers Squibb Company, Clovis Oncology, Pfizer and Other Key Players

Boston Common Asset Management LLC Increases Stock Holdings in Astrazeneca Plc $AZN

Astrazeneca Plc $AZN Shares Bought by Allspring Global Investments Holdings LLC

AstraZeneca: Efzimfotase Alfa Shows Positive Results From Phase III Programme

AstraZeneca Drug Candidate Achieves Mixed Results in Trials for Rare Disease | Morningstar

Author Correction: Phenome-wide analysis of copy number variants in 470,727 UK Biobank genomes

Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial

Promising Manufacturing Stocks To Watch Today - March 30th

Telnyx package latest hit in PyPI supply-chain compromise • The Register

Tozorakimab trial success hands AstraZeneca a crucial edge in the race to crack COPD's hardest-to-treat patients

Guggenheim Raises AstraZeneca Price Target Ahead of Q1 Earnings

MOR Wealth Management LLC Makes New Investment in Astrazeneca Plc $AZN

MOR Wealth Management LLC Takes $526,000 Position in Astrazeneca Plc $AZN - Markets Daily

Pancreatic Adenocarcinoma Treatment Market to Grow at 13% CAGR During 2026-2030, Led by Pfizer, Roche, Merck & Co., Sanofi, Bristol-Myers Squibb, AstraZeneca, Novartis, and GlaxoSmithKline

Recurrent Head and Neck Cancer Squamous Cell Carcinoma Markets and Competition Outlook 2026-2030: Personalized Medicine Drives Revenue Growth, Reaching $4.61 Billion by 2030

Non-Muscle Invasive Bladder Cancer (NMIBC) Market to Grow by $1 Billion During 2026-2030 - Johnson & Johnson, Janssen Research & Development, and Merck & Co. Lead the Competition

Cancer Cachexia Market Outlook Report 2026-2030: Personalized Treatments and Digital Tools Elevate Cancer Cachexia Care; Total Revenue to Grow by $600 Million

Dakota Wealth Management Purchases 5,595 Shares of Astrazeneca Plc $AZN

UK Value Stock Picks Including Serica Energy For Estimated Discount Opportunities

Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial

A renaissance in targeting the PI3K/AKT/mTOR pathway

Global, regional and national burden of ischemic heart disease attributable to suboptimal diet, 1990-2023: a Global Burden of Disease study

USA Financial Formulas Acquires Shares of 10,063 Astrazeneca Plc $AZN

LVW Advisors LLC Decreases Holdings in Astrazeneca Plc $AZN - Markets Daily

LVW Advisors LLC Sells 3,172 Shares of Astrazeneca Plc $AZN - Stock Observer

USA Financial Formulas Takes Position in Astrazeneca Plc $AZN - Daily Political

Manufacturing Stocks To Add to Your Watchlist - March 28th - Markets Daily

Sax Wealth Advisors LLC Makes New $404,000 Investment in Astrazeneca Plc $AZN - Markets Daily

Nordea Investment Management AB Grows Holdings in Astrazeneca Plc $AZN

AstraZeneca COPD Breakthrough Puts Tozorakimab And Valuation In Sharper Focus

Is AstraZeneca (LSE:AZN) Offering Value After Recent Share Price Pullback

AstraZeneca (LON:AZN) Share Price Passes Above 200-Day Moving Average - Here's What Happened - Markets Daily

AstraZeneca COPD Success Tests Regeneron Dupixent Growth Story

UK's FTSE 100 Ends Week Little Changed; AstraZeneca Shares Gain

Morning News Wrap-Up: 3/27/26: Today's Biggest Stock Market Stories | Markets Insider

Astrazeneca (NYSE:AZN) Shares Gap Up - Here's What Happened

AstraZeneca Shares Rise After Lung Drug Hits Goals in Late-Stage Trials - Update | Morningstar

AstraZeneca Stock Rises 4% Over Positive Data From Tozorakimab Study

Stocks to Watch: Unity, Carnival, AstraZeneca - Yahoo Actualités France

Live Nasdaq Composite: Markets Tank as Oil Soars on Mideast Fatigue

AstraZeneca Zips Higher On Its Double Win In COPD Treatment - Yahoo News Canada

AstraZeneca stock jumps 4% after surprise lung disease trial win

AstraZeneca's Tozorakimab Shows Promise in Reducing COPD Flare-Ups, ETPharma

Stocks making the biggest moves premarket: AZN, U, COIN

China approves innovative breast cancer therapy by Daiichi Sankyo, AstraZeneca - Chinadaily.com.cn

AstraZeneca shares rise to top of FTSE 100 as COPD drug clears two pivotal trials

AstraZeneca's Tozorakimab Meets Primary Endpoint In Phase III COPD Trials

Markedsoppdatering om samarbeidet med AstraZeneca

Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial

Innate Pharma SA (IPHA) Full Year 2025 Earnings Call Highlights: Strategic Advances and ...

Apple's Expanding Enterprise Footprint to Boost Sales: What's Ahead?

Innate Pharma Q4 Earnings Call Highlights - Daily Political

Astrazeneca Plc (NYSE:AZN) Receives Average Rating of "Moderate Buy" from Analysts

AstraZeneca (LON:AZN) Share Price Passes Above 200 Day Moving Average - What's Next?

Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous

INNATE PHARMA PRÉSENTE SES RÉSULTATS FINANCIERS ET L'AVANCÉE DE SON PORTEFEUILLE POUR L'ANNÉE 2025

Innate Pharma Reports Full Year 2025 Financial Results and Business Update

4568: Oncology Pipeline Progress Will Drive Further Upside For Shares

AstraZeneca (AZN) Announces EU Approval of Imfinzi for Early Gastric/Gastroesophageal Cancers

2 FTSE 100 blue-chips to consider for a new £20k Stocks and Shares ISA

Hengrui Medicine's Innovative Drug Revenue Accounts for Nearly Sixty Percent, BD Restructuring Internationalization Anchor Value

Professional Advisory Services Inc. Has $28.12 Million Stock Holdings in Astrazeneca Plc $AZN

12 Best UK Stocks to Buy According to Hedge Funds

First-line Nivolumab plus FOLFOXIRI/Bevacizumab in advanced RAS/BRAF-mutated colorectal cancer: efficacy, safety and biomarker discovery from the phase II NIVACOR trial

Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial

£20,000 invested in a Stocks and Shares ISA 5 years ago could now be worth…

Procyon Advisors LLC Has $727,000 Stake in Astrazeneca Plc $AZN - Daily Political

Astrazeneca Plc $AZN Shares Sold by Montecito Bank & Trust - Daily Political

AI-based chest X-ray prioritization in the lung cancer diagnostic pathway: the LungIMPACT randomized controlled trial

Oncology Clinical Trials Market Forecast 2026-2035 - AI Revolutionizes Oncology Clinical Trials: Boosts Recruitment, Optimizes Protocols

Westview Management dba Westview Investment Advisors Invests $3.60 Million in Astrazeneca Plc $AZN

Gradient Investments LLC Raises Stock Holdings in Astrazeneca Plc $AZN

39,136 Shares in Astrazeneca Plc $AZN Bought by Westview Management dba Westview Investment Advisors - Daily Political

AstraZeneca Deepens China Roots With Shanghai Cell Therapy Manufacturing Push

TR/CC CRB Index (TRCCRB) - Investing.com Canada

Large language models in healthcare

Implementation of the NHS England Lung Cancer Screening Programme over 5 years

Assessing AstraZeneca (LSE:AZN) Valuation After A Recent Share Price Pullback

Signet Financial Management LLC Invests $2.57 Million in Astrazeneca Plc $AZN

Central Pacific Bank Trust Division Takes $952,000 Position in Astrazeneca Plc $AZN

Astrazeneca (NYSE:AZN) Raised to Buy at Wall Street Zen

Hilltop National Bank Purchases 7,586 Shares of Astrazeneca Plc $AZN

Hilltop National Bank Acquires 7,586 Shares of Astrazeneca Plc $AZN - Daily Political

AstraZeneca to establish cell therapy production and supply base in Shanghai

Manufacturing Stocks Worth Watching - March 20th - Markets Daily

Park National Corp OH Has $12.82 Million Stock Position in Astrazeneca Plc $AZN

2 Healthcare Stocks to Buy Before They Get Bought Out

Global drug giants double down on China amid trend to build self-reliant supply chains | South China Morning Post

Astrazeneca (NYSE:AZN) Rating Increased to Buy at Wall Street Zen

Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium

A multi-ancestry genome-wide study of tamoxifen metabolism and breast cancer recurrence

Defining the acute BTK-loss transcriptional program in CLL using a BTK degrader

Cellectis publie ses résultats financiers du quatrième trimestre 2025 et de l'exercice 2025 et une mise à jour de ses activités

Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update